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The functions of the two proteins defective in autoso-
mal dominant polycystic kidney disease, polycystin-1
and polycystin-2, have not been fully clarified, but it has
been hypothesized that they may heterodimerize to
form a “polycystin complex” involved in cell adhesion.
In this paper, we demonstrate for the first time the
existence of a native polycystin complex in mouse kid-
ney tubular cells transgenic for PKD1, non-transgenic
kidney cells, and normal adult human kidney. Polycys-
tin-1 is heavily N-glycosylated, and several glycosylated
forms of polycystin-1 differing in their sensitivity to en-
doglycosidase H (Endo H) were found; in contrast, na-
tive polycystin-2 was fully Endo H-sensitive. Using
highly specific antibodies to both proteins, we show that
polycystin-2 associates selectively with two species of
full-length polycystin-1, one Endo H-sensitive and the
other Endo H-resistant; importantly, the latter could be
further enriched in plasma membrane fractions and co-
immunoprecipitated with polycystin-2. Finally, a sub-
population of this complex co-localized to the lateral cell
borders of PKD1 transgenic kidney cells. These results
demonstrate that polycystin-1 and polycystin-2 interact
in vivo to form a stable heterodimeric complex and sug-
gest that disruption of this complex is likely to be of
primary relevance to the pathogenesis of cyst formation
in autosomal dominant polycystic kidney disease.
Autosomal dominant polycystic kidney disease (ADPKD)1 is
the most common inherited human renal disease, affecting up
to 15% of all patients on renal replacement therapy. In the past
7 years, PKD1 and PKD2, the two genes defective in this
disorder, have been identified (1, 2). Nonetheless, the functions
of the two gene products, polycystin-1 and polycystin-2, remain
unclear. Sequence analysis and hydropathy plots suggest that
the PKD1 protein, polycystin-1, is a novel integral membrane
glycoprotein containing a number of extracellular domains pre-
viously described in other proteins involved in cell-cell and
cell-matrix interactions (3). Polycystin-1 is also highly homol-
ogous to the sea urchin sperm receptor for egg jelly (suREJ)
protein, which triggers extracellular Ca2 influx in the acro-
some reaction (4). A recent study demonstrated that polycys-
tin-1 overexpression stimulated tubulogenesis and inhibited
proliferation in Madin-Darby canine kidney cells (5). Therefore,
it seems likely that polycystin-1 plays a multifunctional role in
the regulation of cell differentiation, proliferation, and cation
transport. Polycystin-2, the PKD2 protein, has significant ho-
mology to voltage-activated and transient receptor potential
K, Na, and Ca2 channels (2). A polycystin-2 homologue,
PKD-L, has been shown to reconstitute non-selective Ca2
channel activity in Xenopus oocytes (6), and recent studies
suggest that polycystin-2 can also reconstitute a non-selective
Ca2 channel under certain conditions (7, 8).
The overlapping phenotype of PKD1 and PKD2 patients has
led to the hypothesis that polycystin-1 and polycystin-2 could
function as members of the same signaling pathway or as
interacting partners in a heterodimeric protein complex. Con-
sistent with this hypothesis, co-ordinate expression of polycys-
tin-1 and polycystin-2 in the kidney and other tissues has been
described (9) and recombinant fusion proteins containing the
C-terminal domains of both proteins shown to heterodimerize
in yeast two-hybrid systems (10, 11). Nevertheless, the exist-
ence of a native polycystin-1-polycystin-2 complex has yet to be
demonstrated and is an area of current controversy. There are
two main reasons for this uncertainty. First of all, the subcel-
lular location of both proteins appears to be very different.
There are convincing data demonstrating an exclusive endo-
plasmic reticulum (ER) location for polycystin-2 (12), but yeast
two-hybrid studies have shown that polycystin-2 can also in-
teract with actin-binding proteins such as Hax-1 and CD2-AP
via its C-terminal tail (13, 14). Polycystin-1 immunoreactivity
has been observed in different plasma membrane domains as
well as within cytoplasmic vesicles but not predominantly in
the ER (reviewed in Ref. 15). This non-overlapping distribution
has made it seem less likely that both proteins form a complex
at least within the same membrane domain (see “Discussion”).
Second, there is conflicting evidence as to whether polycystin-2
can reconstitute a functional channel independently of polycys-
tin-1. A recent paper showed that transient overexpression of
polycystin-1 and polycystin-2 but neither one alone increased a
non-selective whole-cell conductance in transfected CHO cells
(16). In this study, surface expression of a putative polycystin-
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1-polycystin-2 channel was inferred by overlapping signals
with a co-transfected surface marker protein (CD4) in individ-
ual cells. However, using different experimental systems, two
other groups later described surface Ca2 channel activity re-
constituted by polycystin-2 alone (7, 8). These differences might
well be cell- or tissue-specific, but the demonstration of poly-
cystin-1-independent polycystin-2 activity could also imply
that the two proteins do not interact directly. This conclusion
would be consistent with one observation of differential poly-
cystin-1 and polycystin-2 expression (17).
The low levels of native polycystin-1 in tissues and cells have
made functional studies of endogenous polycystin-1 very diffi-
cult (15). To overcome this problem, we have generated renal
cell lines from newborn mice transgenic for human PKD1 (18).
These mice express a transgene comprising the entire human
PKD1 gene with its 5- and 3-flanking regions (20 kb up-
stream, 43 kb downstream) but excluding the HG loci (18).
Expression of transgenic polycystin-1 was developmentally reg-
ulated in different tissues including the kidney, and expression
of transgenic polycystin-1 could rescue the embryonically lethal
Pkd1 knockout phenotype observed in pkd1del34 mice (18). We
reasoned, therefore, that cells derived from these animals
might be good models to study polycystin-1 function because
the transgene appeared to be appropriately regulated and the
gene product processed, transported, and expressed as a func-
tional protein in vivo. Here we report for the first time the
isolation, biochemical characterization, and subcellular local-
ization of a polycystin-1-polycystin-2 protein complex in PKD1
transgenic kidney cells and also describe the existence of this
complex in non-transgenic kidney cells and normal adult hu-
man kidney.
EXPERIMENTAL PROCEDURES
Generation of PKD1 Transgenic Lines—The generation of three foun-
der PKD1 transgenic mice has been described in a previous paper (18).
Like the endogenous murine protein, expression of transgenic polycys-
tin-1 is markedly down-regulated between 2 and 4 weeks postnatally
(18). We decided therefore to generate cell lines from newborn kidneys
(embryonic day 18). Renal cells were cultured using standard tech-
niques from eight newborn (embryonic day 18) mice (M1–M8) resulting
from an F1 cross between a heterozygote PKD1 transgenic mouse
(TPK3) and a transgenic mouse homozygous for the temperature-sen-
sitive T antigen (Immortomouse) (19). In brief, renal tissue was minced
and digested with type 1 collagenase, and tubular fragments plated
onto collagen-coated flasks. Cells were grown in low serum selective
medium to encourage epithelial outgrowth (Dulbecco’s modified Eagle’s
medium/F-12 supplemented with 5% Nuserum) and cultured at 33 °C in
the presence of recombinant mouse -interferon (Roche Molecular Bio-
chemicals, Mannheim, Germany) to activate T antigen expression (20).
Two lines (M7 and M8) were selected for further study. Because
collecting ducts consistently show the highest polycystin-1 expression
in developing and mature kidney (15), cells of collecting duct origin
were isolated from primary culture by lectin affinity cell separation
using the lectin DBA, which is exclusively expressed at the apical cell
surface of collecting duct cells in mouse kidney (21). Cells positive for
biotinylated DBA (Vector) were then purified using streptavidin-conju-
gated magnetic beads (M280 beads, Dynal) as previously described (21).
These cells were found to express DBA at the cell surface but not the
lectin, Lotus tetragonolobus, which is expressed by proximal tubular
segments (data not shown). Cells were studied mainly at early passage
(up to passage 15) and retained epithelial morphology throughout.
Northern Blotting—The isolation of the PKD1 probes 3A3 (single
copy) and JH8 (duplicated region) and Pkd1 probe MS9 (exons 3–10)
has been reported in previous papers (1, 18). A new N-terminal probe
(PKD1NT) was generated as a 1.4-kb BglII-NotI fragment (nucleotides
1–1232). A 0.9-kb mouse utrophin EcoR1 fragment (nucleotides 425–
1330) was used to detect a full-length utrophin transcript (13 kb) (gift of
Dr. N. Y. Loh and Prof. K. E. Davies). Total RNA was extracted using
TRIzol reagent (Invitrogen, Paisley, UK) from cultured cells as de-
scribed previously (22). The extracted RNA was quantified both by
optical density at 260 nm and UV densitometry of the 18 S rRNA
subunit. 15 g of total RNA was run on a 1.2% (w/v) agarose/MOPS/
formaldehyde gel, capillary-blotted onto Hybond N (Amersham Bio-
sciences, Bucks, UK), and cross-linked with 70 mJ/cm2 UV radiation
(UV cross-linker, Amersham Biosciences). This membrane was probed
FIG. 1. Modular structure of polycystin-1 and polycystin-2 showing the different domains of each protein to which polycystin-1
(7e12, NT2B, BD3) and polycystin-2 (p30) antibodies were generated. For further details, refer to “Experimental Procedures.”
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with a [32P]dCTP random-primed (Prime a gene, Promega, UK) specific
DNA probe. Specific signals were obtained by exposing the blot to
Biomax MS film for up to 72 h. The resulting autoradiograph was
quantitated by scanning densitometry using a Bio-Rad GS-690 densi-
tometer and Molecular Analyst version 4 software. Values were cor-
rected for loading using repeat probing with the housekeeping gene
cyclophilin (23).
Generation of Antibodies to Polycystin-1 and Polycystin-2—The gen-
eration of a mAb to the leucine-rich repeat (LRR) motif of human
polycystin-1 (7e12), specific rabbit antisera to the C-terminal 258 amino
acids of human polycystin-2 (p30), and C-terminal 205 amino acids of
human polycystin-1 (BD3) have been described in previous papers (9,
24, 25). In this paper, we report the generation of new rabbit polyclonal
antisera (PKD1NT2A, PKD1NT2B) to a large N-terminal region
(HincII fragment, bp 358–3790) of human polycystin-1 (amino acids
50–1144) containing the LRR motif up to the fifth PKD repeat domain
(3). A bacterial protein containing this region fused to a thioredoxin
histidine tag was prepared in Escherichia coli (BL21 DE3) using the
expression vector pET32a (Invitrogen, Groningen, The Netherlands).
The protein was initially prepared as inclusion bodies, solubilized in 6
M guanidine, and purified by nickel affinity chromatography (9). It was
then dialyzed against phosphate-buffered saline and the soluble protein
used to immunize rabbits. The domains to which different polycystin-1
(7e12, NT2B, BD3) and polycystin-2 (p30) antibodies were raised are
illustrated in Fig. 1.
Affinity Purification—The generation and characterization of p30, a
specific antiserum to a fusion protein containing the C-terminal 258
amino acids of human polycystin-2, has been described in a previous
publication (9). More recently, this antiserum has also been found to
block cation channel activity reconstituted by recombinant polycystin-2
(7). p30 was further purified (afp30) by affinity purification to the same
fusion protein coupled to cyanogen bromide (CNBr)-activated Sepha-
rose beads (Sigma) according to the manufacturer’s instructions. The
generation of rabbit antisera to a large N-terminal region of human
polycystin-1 (PKD1NT2A, PKD1NT2B) is described above. These anti-
sera were affinity-purified (afNT2A and afNT2B) to the same fusion
protein immobilized on a polyvinylidene difluoride membrane using a
previously published method (26).
Antibody Biotinylation—An IgG fraction of p30 was isolated using
Protein A beads and biotinylated with EZ-Link Sulfo-NHS-Biotin
(Pierce, Chester, UK) according to the manufacturer’s instructions.
Immunoblotting—Plasma membrane enriched fractions from human
kidney were prepared and processed for immunoblotting as previously
described (9, 24). The binding of biotinylated antibody was detected
with horseradish peroxidase-conjugated streptavidin (Amersham Bio-
sciences) after an additional blocking step with an avidin/biotin block-
ing kit (Vector Laboratories, Burlingame, CA) to remove endogenous
biotin signals.
Immunoprecipitation—Initial experiments demonstrated that the
polycystin-1-polycystin-2 complex was equally present in cells cultured
at permissive (33 °C) and non-permissive (37 °C for 48 h omitting -in-
terferon) temperatures (data not shown). Subsequent immunoprecipi-
tation experiments were therefore performed on cells grown at 33 °C. In
brief, cell lysates or membrane fractions were obtained by extraction at
4 °C using detergent lysis buffer (1% Triton X-100, 0.5% Nonidet P-40,
150 mM sodium chloride, 25 mM sodium phosphate, pH 7) supplemented
with a commercial protease inhibitor mixture (Complete™, Roche Mo-
lecular Biochemicals) and precleared for 1 h using recombinant Protein
G-Sepharose beads (Gamma-bind, Amersham Biosciences). Protein G-
antibody conjugates were then added to the cleared lysates and allowed
to incubate on a rotator overnight at 4 °C. After extensive washes with
the binding buffer, the beads were incubated with either reducing
(containing 5% -mercaptoethanol) or non-reducing sample buffer at
50 °C for 30–60 min and processed for immunoblotting.
Glycosylation Analysis—Membrane fractions from kidney or cul-
tured cells were solubilized in 1% SDS, 10 mM Tris-HCl (pH 7.5)
supplemented with a Complete™ mini protease inhibitor mixture and 1
mM phenylmethylsulfonyl fluoride. Lysates corresponding to 10–50 g
of total protein were treated with 500 units of endoglycosidase H (Endo
H) or N-glycosidase F (PNGase F) according to the manufacturer’s
protocols (Roche Molecular Biochemicals) prior to SDS-PAGE and im-
munoblot analysis.
Subcellular Fractionation—Different membrane fractions were pre-
pared from transgenic cells or human kidney tissue by density gradient
ultracentrifugation. In brief, a postnuclear supernatant was first pre-
pared after Dounce homogenization of a cell pellet or tissue homogenate
by centrifugation at 1000 rpm for 10 min. A total cell membrane pellet
was then isolated by centrifugation at 100,000  g for 1h at 4 °C. Cell
FIG. 2. Polycystin-1, PKD1, and Pkd1 expression by PKD1 transgenic and non-transgenic kidney cells. Four animals (M1, M3, M6,
and M7) from a litter of eight newborn mice were found to carry the PKD1 transgene by Southern blot. A, Western blotting of cell lysates with a
polycystin-1 N-terminal mAb (7e12) showing the presence of several high molecular mass bands (400 kDa) in these four lines (6% gel,
SDS-PAGE). Data for M5 is not displayed on this gel. B, Western blotting of a transgenic (M7) and non-transgenic line (M8) for polycystin-1 (7e12),
polycystin-2 (p30), and the SV40-T antigen (pAb416). Note that, although polycystin-1 expression remains undetectable in the non-transgenic line
M8, equal amounts of polycystin-2 and SV40-T antigen were present in both lines. 20 g of total cell protein was loaded per lane. C, Northern
analysis of RNA extracted from M7 and M8 lines. A single 14-kb band was detected in M7 alone with the C-terminal PKD1 probe 3A3, but an
additional band of 9.5 kb was also detected using probes to the middle (JH8) portion of PKD1. On prolonged exposure (72 h), single 14-kb bands
can be seen in both lines with a Pkd1 probe, MS9. Cyclophilin (1.8 kb) was used as an internal control for loading and RNA integrity.
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membranes or post-nuclear supernatant (human kidney) were then
layered onto a continuous 0–15% Optiprep (Sigma, Poole, UK) gra-
dient and centrifuged at 200,000  g for 3h at 4 °C using a swinging
bucket rotor. Seventeen fractions were recovered from the top, con-
centrated, and analyzed for the presence of polycystin-1 (7e12), poly-
cystin-2 (p30), and marker organelle proteins such as calnexin (ER),
GM130 (Golgi), and Na-K-ATPase 1 subunit (plasma membrane)
by immunoblotting. The relative abundance of each protein within
individual fractions was quantitated by scanning densitometry and
expressed as relative specific activity (FiPt/PiFt) where Fi  quantity
of the marker in fraction i (arbitrary units), Pi  protein content of
fraction i (mg), Pt  total cellular protein (mg), and Ft  total cellular
content of the marker (arbitrary units).
Immunofluorescence—Cells were grown on collagen-coated glass cov-
erslips and were fixed with freshly prepared 4% paraformaldehyde or
ice-cold methanol-acetone. Alternatively, they were extracted for 10
min with 0.5% Triton X-100 prior to fixation using a previously pub-
lished protocol (27). Dual-color immunofluorescence was performed us-
ing 7e12 (polycystin-1) and afp30 (polycystin-2), respectively. Controls
included cells stained with the primary antibody omitted, an irrelevant
mouse IgG1 mAb (Serotec, Kidlington, UK) as a control for polycystin-1,
or a non-immune rabbit IgG fraction (Dako, Ely, UK) as a control for
polycystin-2. The specificity of polycystin-2 staining was also demon-
strated by pre-incubating afp30 with a polycystin-2 C-terminal fusion
protein as previously described (9). TRITC-labeled wheat germ agglu-
tinin (Vector Laboratories) was used to label the Golgi and an antibody
to Sec 61 (gift of Dr. T. Rapoport, Harvard Medical School, Cambridge,
MA) was used to label the ER. Antibody binding was visualized using
fluorescein isothiocyanate-conjugated goat anti-mouse IgG and TRITC-
labeled goat-anti-rabbit secondary antibodies.
Materials—All chemicals were purchased from Sigma (Poole, UK)
unless otherwise stated. Antibodies to calnexin, E-cadherin, and
GM130 were purchased from BD Transduction Laboratories (Oxford,
UK). mAbs to utrophin (MANCHO3, MANCHO7) and SV40-T antigen
(pAb416) were gifts of Prof. G. E. Morris and Dr. P. Jat, respectively.
COS-1 cells were a gift of Dr. D. L. Simmons (University of Oxford,
Oxford, UK).
RESULTS
Transgenic Renal Cells Express Full-length Human Polycys-
tin-1—Four PKD1 transgenic cell lines were generated from a
litter of eight newborn mice resulting from an F1 cross between
a heterozygote PKD1 transgenic mouse (TPK3) and a mouse
homozygous for the temperature-sensitive T antigen (Immor-
tomouse). These lines were shown to express high levels of
full-length human polycystin-1 by immunoblotting with the
N-terminal mAb, 7e12 (Fig. 2A). Polycystin-1 was detected as
several (3–4) bands of high molecular mass (400 kDa) in
these cells and also as several smaller minor bands (220 kDa)
visible on prolonged exposure (compare Figs. 2A and 4A). The
polycystin-1 antibody used (7e12) was raised to the flank-LRR-
flank region within the N terminus of human polycystin-1 (Fig.
1) (24) but does cross-react with murine polycystin-1 (Fig. 5A).
However, the native murine protein was only detectable by
immunoblotting at much higher protein concentrations (300 g
of protein; data not shown) in non-transgenic cells (M8) but not
at the lower protein concentrations (20 g) shown here (Fig.
2B). In contrast, polycystin-2 and the SV40-T antigen were
present in equivalent amounts in both transgenic (M7) and
non-transgenic (M8) cells (Fig. 2B). Thus, overexpression of
polycystin-1 had no effect on steady-state levels of polycystin-2.
Using probes to coding sequences within the C-terminal tail
(3A3), the middle extracellular portion (JH8), and the extreme
N terminus (PKD1NT) of PKD1 (data not shown), the presence
of a full-length 14-kb human transcript was demonstrated on
Northern analysis in M7 cells but not in M8 (Fig. 2C). The
13-kb murine dystrophin transcript was used as a size marker.
M7 cells also express a major RNA species of approximately 9.5
kb in size (detectable with JH8 and PKD1NT), which contains
the predicted extracellular portion of PKD1 but which lacks the
C-terminal tail. This is likely to represent a splice form of the
gene and may account for a form of the protein (180 kDa)
especially prominent in transgenic brain (18). Several potential
splice sites of the PKD1 transcript have been identified: intron
12 (mouse Pkd1), intron 16 (human), and exon 24 (human) (3,
28), but the latter would seem to fit best with the estimated size
of the alternative transcript. The absence of other smaller RNA
species also suggests that not all the small N-terminal frag-
ments detected by immunoblotting can be related to alternative
splicing. Using a mouse-specific probe (MS9), we found that
both lines expressed equally low levels of full-length Pkd1
mRNA of the same size after prolonged exposure (72 h) but no
other splice forms were detected under these conditions (Fig.
2C). Thus, expression of transgenic PKD1 did not affect steady-
state expression of the endogenous Pkd1 gene, even though
expression of PKD1 was up to 22 times greater than that of
Pkd1 by densitometry. This is consistent with a previous esti-
FIG. 3. Glycosylation analysis of polycystin-1 and polycystin-2
in transgenic cell lysates (A), NHK (B), and COS-1 membranes.
Polycystin-1 and polycystin-2 expression was detected using 7e12 and
p30, respectively. Both polycystin-1 and polycystin-2 are significantly
N-glycosylated, as shown by their apparent shift in molecular mass
following PNGase F treatment. Significantly, an Endo H-resistant poly-
cystin-1 fraction (400 kDa) was observed in M7 lysates, NHK, and
COS-1 cells. With prolonged exposure, smaller (220 kDa) Endo H- and
PNGase F-sensitive fragments can be visualized in M7 lysates by im-
munoblotting with 7e12; these are likely to represent N-terminal poly-
cystin-1 species. Note also that a minor unglycosylated cross-reactive
band (*) can sometimes be seen in NHK and COS-1 cells above the
220-kDa size marker with longer exposure times; this is unlikely to
represent a polycystin-1 species. In contrast, polycystin-2 was sensitive
to Endo H and PNGase F in all three preparations. The arrowhead in A
shows the position of the unglycosylated endogenous protein, utrophin,
used as a size marker (400 kDa) and as an internal control for protein
integrity and loading. 30–100 g of total protein were loaded per lane
(5% gel, SDS-PAGE). The results shown are a representative experi-
ment of three performed.
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mate of up to 28 copies of the transgene in this founder animal
(TPK3) by Southern analysis (18).
Glycosylation Analysis of Polycystin-1 and Polycystin-2—
Analysis of the secondary structure of human polycystin-1 pre-
dicts 60 putative external N-linked glycosylation sites, but the
glycosylation profile of polycystin-1 has not been previously
studied (3). Using the enzyme PNGase F, which efficiently
cleaves N-linked carbohydrate groups, we demonstrate that
human polycystin-1 is heavily N-glycosylated as indicated by a
significant size shift in its molecular mass following enzymatic
deglycosylation (Fig. 3A). Of interest, both larger (400 kDa)
and smaller (220 kDa) forms of the protein detected by this
antibody showed a major size shift after PNGase F treatment,
indicating that they are likely to represent specific N-glycosy-
lated polycystin-1 species. The dystrophin-related protein,
utrophin, is unglycosylated and has a molecular mass of ap-
proximately 400 kDa (29). Reprobing these membranes with a
utrophin antibody (MANCHO3) revealed that the highest
forms of polycystin-1 had a molecular mass of 400 kDa after
PNGase F treatment (Fig. 3A). The finding that utrophin was
unaffected by enzyme treatment with PNGase F (and Endo H)
also confirms that the existence of these smaller polycystin-1
bands is unlikely to have resulted from proteolytic degradation
either during extraction or by contaminating proteases in the
commercial enzyme preparations. The predicted unglycosy-
lated molecular mass of polycystin-1 is 460 kDa (3).
Because several high molecular weight polycystin-1 bands
(up to four) were consistently detected, we wondered if other
differences in glycosylation might account for some or all of
these species. Endoglycosidase H is an enzyme that specifically
cleaves high mannose type oligosaccharides from the protein
backbone (30). Resistance to Endo H is typically acquired as the
protein undergoes further post-translational modification of
carbohydrate residues in the Golgi (30). Using this enzyme, we
found that the highest molecular weight band was Endo H-
resistant, whereas the other three bands were Endo H-sensi-
tive (Fig. 3A). Biochemically, this Endo H-resistant fraction
should have reached the cis-Golgi and could potentially be
targeted to the plasma membrane.
To confirm that these findings were not restricted to trans-
genic human polycystin-1, normal adult human kidney (NHK)
membrane fractions were subjected to enzymatic deglycosyla-
tion with either PNGase F or Endo H. Parallel studies were
also performed with COS-1, a cell line that we had previously
shown to express both polycystin-1 and polycystin-2 (9, 24). As
shown in Fig. 3B, a high molecular weight Endo H-resistant
polycystin-1 fraction was also detected in NHK and COS-1
cells. However, an Endo H-sensitive polycystin-1 fraction was
not clearly visualized in NHK and faintly seen in COS-1 cells,
possibly because of the much lower levels of native polycystin-1
compared with that expressed in transgenic cells.
Analysis of the secondary structure of polycystin-2 predicts
five external N-linked glycosylation sites in this protein.
PNGase F treatment confirmed that both human and murine
FIG. 4. Isolation of a polycystin-1-polycystin-2 protein complex from M7 transgenic cell lysates. Immunoprecipitated polycystin-1 and
polycystin-2 were detected by immunoblotting with 7e12 and biotinylated p30, respectively. A, the N-terminal polycystin-1 antibody PKD1NT2B
precipitated several high (400 kDa) and low (220 kDa) molecular mass polycystin-1 bands, whereas polycystin-2 co-immunoprecipitated with
the two highest molecular mass polycystin-1 bands normally present as minor bands in total cell lysate. These two bands correspond to full-length
polycystin-1 because they are also immunoprecipitated by a C-terminal polycystin-1 antibody, BD3. Non-immune rabbit serum (NIS) and
pre-immune sera (data not shown) served as negative controls. The lysate lanes contained 30 g of protein, and each IP lane represents protein
immunoprecipitated from 125 g (PKD1NT2B) or 500 g (p30) of total cellular protein (5% gel, SDS-PAGE). A representative gel of three
experiments is displayed. The arrowhead indicates the highest molecular weight polycystin-1 band detected that is Endo H-resistant (see below).
B, immunoprecipitated polycystin-1 was treated with the deglycosylating enzyme Endo H () or enzyme buffer (). The identical results with p30
and BD3 confirm that polycystin-2 co-immunoprecipitated with two full-length polycystin-1 species, one Endo H-resistant (arrowhead) and the
other Endo H-sensitive. A single Endo H-resistant band (arrowhead) and up to three Endo H-sensitive high molecular weight polycystin-1 bands
were immunoprecipitated by PKD1NT2B. C, polycystin-2 was immunoprecipitated by p30 and co-immunoprecipitated by the polycystin-1
antibodies, PKD1NT2B and BD3. Each IP lane represents protein immunoprecipitated from 250 g (p30) or 500 g (PKD1NT2B, BD3) of total cell
lysate. D, a mAb to utrophin (MANCHO7) does not immunoprecipitate polycystin-1 or polycystin-2 from M7 lysates. An irrelevant mouse IgG2a
mAb (Control) was used to show the specificity of MANCHO7. Utrophin was detected by immunoblotting with MANCHO3. The lysate lanes
represent 30 g of total protein loading, and the IP lanes represent protein immunoprecipitated from 500 g of total lysate.
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polycystin-2 are significantly N-glycosylated, but, unlike poly-
cystin-1, native polycystin-2 was sensitive to Endo H in PKD1
transgenic cells, COS-1 cells, and normal adult human kidney
(Fig. 3). These results are in agreement with a previous study
of polycystin-2 (12). The calculated unglycosylated molecular
mass of polycystin-2 is 110 kDa, so this suggests that the
glycosylated molecular mass is 110 kDa (2).
Polycystin-2 Interacts with Full-length Polycystin-1—In pre-
liminary studies, 7e12 did not efficiently immunoprecipitate
polycystin-1. To study the potential interaction between the
two polycystin proteins, new polycystin-1 antiserum was there-
fore generated to a large N-terminal region of human polycys-
tin-1 (PKD1NT2A, PKD1NT2B) (Fig. 1). Both antisera were
found to be equally efficient in precipitating both large (400
kDa) and smaller (220 kDa) polycystin-1 bands from trans-
genic cells and tissues (Fig. 4A); PKD1NT2B was used in sub-
sequent experiments. Although up to four high molecular
weight bands were enriched by PKD1NT2B, we found that p30
immunoprecipitated only the two highest molecular weight
polycystin-1 bands (Fig. 4A). Identical results were found with
affinity-purified antisera afp30 and afNT2B (data not shown).
Using a previously described polycystin-1 C-terminal antibody
(BD3), we subsequently confirmed that the two bands co-im-
munoprecipitated by p30 represent full-length polycystin-1
(Fig. 4A). Pre-immune sera from PKD1NT2A, PKD1NT2B, and
p30 rabbits did not immunoprecipitate polycystin-1 or polycys-
tin-2 (data not shown).
Further analysis using the enzyme Endo H enabled us to
distinguish two subpopulations of full-length polycystin-1, i.e.
Endo H-resistant and Endo H-sensitive species capable of in-
teraction with polycystin-2 (Fig. 4, B and C). This suggests that
polycystin-2 first associates with polycystin-1 in the ER/cis-
Golgi, and this complex undergoes further maturation by un-
dergoing complex glycosylation through the Golgi prior to in-
sertion into the plasma membrane. In addition to these two
bands, two other Endo H-sensitive high molecular weight poly-
cystin-1 bands were immunoprecipitated by PKD1NT2B but
not recognized by BD3 (Fig. 4B). Because BD3 recognizes an
epitope within a 205-amino acid C-terminal sequence of poly-
cystin-1 (Fig. 1), it is highly likely that these two bands repre-
sent truncated forms of polycystin-1 containing most of the
polycystin-1 sequence but lacking the C-terminal tail. The
specificity of these findings is indicated by the negative results
obtained using non-immune serum (Fig. 4, A and C), pre-
immune serum (data not shown), a mAb to an abundant cellu-
lar protein, utrophin (Fig. 4D), and an irrelevant mouse mAb
(Fig. 4D) for combined immunoprecipitation and immunoblot-
ting studies.
To exclude the possibility that the polycystin-1-polycystin-2
complex identified from transgenic cells might be the result of
overexpression of polycystin-1, the same co-immunoprecipita-
tion experiments were carried out on non-transgenic cells (M8),
COS-1 cells, and NHK membranes. As illustrated in Fig. 5,
polycystin-1 and polycystin-2 also co-immunoprecipitated in
non-transgenic M8 cells. Native polycystin-1 expression in M8
was very low and could only be demonstrated by using 4–6
times as much protein in a combined immunoprecipitation/
immunoblotting protocol and by increasing both the concentra-
tion and incubation time of primary and secondary antibodies
used for detection (Fig. 5A). Nevertheless, immunoprecipita-
tion with BD3 and p30 enriched two high molecular mass
(400 kDa) bands as observed in the M7 transgenic cells,
whereas NT2B enriched both high (400 kDa) and low (220
kDa) molecular mass species in these cells (Fig. 5A). In both M7
and M8 cells, only a minor fraction of polycystin-2 appeared to
associate with either transgenic or native polycystin-1 (com-
FIG. 5. Isolation of a native polycystin-1-polycystin-2 protein complex from M8 non-transgenic cells and COS-1 cells. A, polycystin-2
co-immunoprecipitated with native polycystin-1 in M8 cells but the abundance of this complex was only detectable with higher protein
concentrations, higher antibody concentrations, and prolonged exposure. Left panel, starting material of 0.5, 1, and 2 mg of total cell lysate for
immunoprecipitation (IP) with p30. Middle panel, 12 times the starting material was used for immunoprecipitation of polycystin-2 with BD3 (3 mg)
compared with p30 (0.25 mg). Right panel, smaller molecular mass bands (220 kDa) are seen to be enriched by NT2B from M8 cell lysates. In
contrast, like p30, BD3 enriched only two high molecular weight polycystin-1 bands in M8 cells. These findings are identical to those from M7 cells
(see Fig. 4). B, co-immunoprecipitation of polycystin-1 and polycystin-2 from COS-1 cells. Equal amounts of starting material (1 mg) were used for
immunoprecipitation with p30 and BD3. The arrowhead indicates the position of monomeric polycystin-2. Two other cross-reactive bands are
visible with longer exposure; the lower band (100 kDa, *) in the BD3 lane represents partially reduced rabbit immunoglobulin heavy chains; the
higher band may represent an endogenous biotinylated protein.
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pare Figs. 4C and 5A). We estimate by densitometry that, in
both cells, this is less than 10% (7–8%) of total steady-state
polycystin-2 concentrations. These results imply that polycys-
tin-2 binding to polycystin-1 remains tightly regulated in
transgenic cells despite the large increase in polycystin-1
expression.
Similarly, a polycystin-1-polycystin-2 complex was identified
in COS-1 cells (Fig. 5B) and NHK membranes (Fig. 6A). As
with M8 cells, NT2B also enriched low molecular weight poly-
cystin-1 species in COS-1 (data not shown) and NHK (Fig. 6A),
confirming that their existence was not the result of polycys-
tin-1 overexpression. As they are minor species in all these
native preparations, they are more abundant in transgenic
cells and therefore more easily detectable.
Co-sedimentation and Co-immunoprecipitation of Endo H-
resistant Polycystin-1 and Polycystin-2 from Plasma Membrane
Fractions of Transgenic Cells—To further define the subcellu-
lar location of the Endo H-resistant and Endo H-sensitive poly-
cystin-1 species capable of interaction with polycystin-2, differ-
ent subcellular membrane compartments were prepared from
transgenic cell membranes by density gradient centrifugation.
We obtained a consistent and clear separation between the
lightest fractions (F1–F3) enriched for plasma membrane pro-
teins (1 subunit, Na-K-ATPase), the middle fractions (F6–
F8) for a Golgi protein GM130, and the heaviest fractions
(F12–F17, especially F16 and F17) for an ER-resident protein
calnexin (Fig. 7A). Differential distribution of polycystin-1 sub-
populations was found between these fractions. In particular,
the highest molecular weight Endo H-resistant polycystin-1
band was enriched in plasma membrane fractions, whereas the
high molecular weight Endo H-sensitive bands were found
mainly in the heavier ER fractions (Fig. 7A). Polycystin-2 was
detected mainly in ER fractions but was visible in Golgi frac-
tions and a small subpopulation also clearly detectable in
plasma membrane fractions (Fig. 7, A and B). Significantly,
these plasma membrane fractions completely excluded cal-
nexin but, as expected, were highly enriched for the 1 subunit
of Na-K-ATPase (82% of total). Importantly, Endo H-resist-
ant polycystin-1 could be selectively co-immunoprecipitated
with polycystin-2 from the lightest fractions (F1 and F2), con-
firming that they form a heterodimeric complex located in
plasma membranes (Fig. 7C).
Co-sedimentation of Polycystin-1 and Polycystin-2 in Plasma
Membrane Fractions of Normal Human Kidney—Although we
demonstrated the existence of a complex of polycystin-1 and
polycystin-2 in plasma membrane-enriched fractions from nor-
mal human kidney (Fig. 6A), the method of isolation used does
not reliably exclude a minor contamination with ER mem-
branes (24). Density gradient centrifugation was therefore
used to obtain clearer separation between plasma membranes
and ER membranes to demonstrate the presence of populations
of polycystin-1 and polycystin-2 in plasma membranes. As
shown in Fig. 6B, human kidney membranes separated in
slightly different peaks to that seen with M7 cells (Fig. 7A)
under the same gradient conditions. The 1 subunit of Na-
K-ATPase was more evenly distributed throughout the gradi-
ent than with M7 cells, although it was clearly detected in the
lightest fractions (F3–F5), which excluded Golgi (GM130)- and
ER (calnexin)-resident proteins. Calnexin was not detected in
these fractions even after prolonged exposure (30 min, Fig. 7A).
Thus clear separation between these lighter plasma mem-
branes (F3–F5) and heavier ER membranes (F8–F17, peak in
F12–F14) was achieved. As expected, Golgi membranes sedi-
mented in the middle fractions (F6–F9), but calnexin was de-
tected in F7–F9 after prolonged exposure. Under these condi-
tions, polycystin-1 was found mainly in plasma membrane and
Golgi fractions, whereas polycystin-2 was found predominantly
in the ER. Nevertheless, as observed with M7 cells, significant
polycystin-2 expression was also detectable in Golgi fractions
and a minor fraction clearly present in plasma membranes
(Fig. 6B). The highest relative specific activities for polycys-
tin-2 and calnexin were found in F14 (3.59, 4.27), confirming
that most of kidney polycystin-2 is present in the ER. However,
a minor fraction of polycystin-2 was also found in plasma mem-
brane fractions that excluded calnexin, e.g. F4 (relative specific
activity 0.21 and 0), respectively. This fraction also had the
highest relative specific activity for polycystin-1 (12.4).
Higher Molecular Mass Forms of Polycystin-2—In addition to
a band of 110 kDa corresponding to monomeric polycystin-2
from transgenic cell lysates, p30 immunoprecipitated at least
two other high molecular mass polycystin-2 bands, which were
more prominent under non-reducing conditions (Fig. 8A); sim-
ilar results were found in non-transgenic cells (Fig. 8A). To
ascertain if these higher molecular mass bands might repre-
sent physiological homodimers of polycystin-2, NHK mem-
branes were run under non-reducing conditions and detected
FIG. 6. Isolation of a polycystin-1-polycystin-2 protein complex
from normal human kidney. A, polycystin-1 and polycystin-2 were
present in very low abundance in NHK but could be immunoprecipi-
tated by PKD1NT2B and p30, respectively. As with M7 cells, both
antibodies also co-immunoprecipitated the other polycystin partner,
although the polycystin-2 signal with PKD1NT2B was much weaker.
No specific band was detected after immunoprecipitation with non-
immune serum (NIS). Each IP lane represents protein immunoprecipi-
tated from 0.5 mg (p30) to 2 mg (NT2B) of total cell lysate. B, using
similar conditions for density gradient centrifugation as described in
Fig. 7, polycystin-1 and polycystin-2 could be detected in plasma mem-
brane fractions (F3–F5) from NHK and both proteins were also present
in Golgi fractions (F6–F9). Polycystin-2 was, however, most abundant
in the denser ER fractions (F12–F14), as seen in the M7 cells. A
representative experiment of two is displayed.
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with p30. As shown in Fig. 8B, the two higher molecular mass
bands became equally prominent as the full-length monomeric
polycystin-2 band detected by p30 under reducing conditions
(110 kDa), suggesting that they could represent native polycys-
tin-2 oligomers. Alternatively, these higher molecular mass
species could represent polycystin-2 bound to other (as yet
unidentified) proteins.
Immunolocalization of Polycystin-1 and Polycystin-2 in
Transgenic Cells—Both polycystin-1 (7e12) and polycystin-2
(p30) antibodies cross-react with the murine proteins. Polycys-
tin-1 expression in M7 cells was clearly more intense than in
M8 cells by immunofluorescence (Fig. 9). Most of the signal
detected was intracellular and co-localized with both ER and
Golgi marker proteins (data not shown), consistent with the
results of subcellular fractionation (Fig. 7). Previous studies
had shown that three pools of cadherin-catenin complexes (in-
tracellular, at the lateral membrane, and at the apical junc-
tional complex) in Madin-Darby canine kidney cells can be
distinguished in part by their differential solubility in the
detergent Triton X-100 (27). Taking the same approach, we
found detectable labeling for polycystin-1 at the lateral cell
surfaces after removal of the intracellular polycystin-1 pool
with Triton X-100 (Fig. 9). As previously shown, E-cadherin
expression was retained within the basolateral membrane do-
main under these conditions (Fig. 9) (27).
Like polycystin-1, the polycystin-2 signal was predominantly
intracellular, but, unlike polycystin-1, polycystin-2 expression
was of equal intensity in both lines. As with polycystin-1, a
subpopulation of membrane-associated polycystin-2 was iden-
tified after extraction with Triton X-100 (Fig. 9). Dual immu-
nofluorescence studies further showed co-localization of both
proteins with largely but not completely overlapping signals in
extracted and non-extracted cells (Fig. 9, C and F). We also
confirmed the retention of a significant proportion of polycys-
tin-1, polycystin-2, and E-cadherin in the insoluble cell pellet
by immunoblotting following prolonged (1 h) extraction with
0.5% Triton X-100 (Fig. 8C).
Because the polycystin-2 antibody, p30, does not distinguish
between different forms of polycystin-2, it is possible that the
polycystin-2 signal detected in lateral cell membranes could
represent both polycystin-2 bound to polycystin-1 as well as
polycystin-2 monomers/multimers. There is disagreement as to
whether polycystin-2 can be independently targeted to the
plasma membrane (7, 8, 16). However, our data would suggest
that the polycystin-2 signal detected is most likely to represent
that bound to polycystin-1 as part of a heterodimeric complex.
DISCUSSION
The identification of PKD1, the major gene mutated in
ADPKD, was a major step in elucidating the pathogenesis of
this common hereditary disease. However, progress in under-
standing the normal function of the PKD1 protein, polycys-
FIG. 7. Isolation of a plasma membrane polycystin-1-polycystin-2 complex from M7 transgenic cells by subcellular fractionation
and co-immunoprecipitation. A, using density gradient centrifugation, fractions enriched for the plasma membrane protein subunit -Na-
K-ATPase (F1–F3), the Golgi protein GM130 (F6–F8), and the ER protein calnexin (F12–F17) were isolated and analyzed for the presence of
polycystin-1 (7e12) and polycystin-2 (p30). The highest molecular weight Endo H-resistant polycystin-1 band was found to be highly enriched in
a plasma membrane fraction F1, whereas the lower Endo H-sensitive polycystin-1 bands were enriched in the denser ER fractions F12–F17.
Polycystin-2 was present predominantly in the same ER fractions but was also detectable in Golgi (F6–F8) and plasma membrane fractions (F1
and F2). A representative experiment of three is displayed. B, the abundance of polycystin-2 (PKD2) in relation to specific organelle marker
proteins in each fraction was quantified by scanning densitometry and expressed as relative specific activity (see “Experimental Procedures”). Note
that the distribution pattern of polycystin-2 is very different from that of the ER resident protein calnexin. C, unlike total cell membranes (Total),
a single Endo H-resistant polycystin-1 band was co-immunoprecipitated with polycystin-2 from plasma membrane fractions (PM) by p30.
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tin-1 has been slow. This has been in part because of the size
and complexity of the protein, the low levels of the native
protein, the paucity of specific reagents, and the difficulty in
generating cell lines expressing full-length recombinant poly-
cystin-1 (reviewed in Ref. 15).
Progress in understanding the function of the PKD2 protein,
polycystin-2, has been more rapid. Recent studies suggest that
it is an N-glycosylated integral membrane protein with signif-
icant homology to voltage-activated and transient receptor po-
tential Ca2 channels (2). Unexpectedly, glycosylation analysis
of native and recombinant polycystin-2 has shown that it is
completely Endo H-sensitive, suggesting that most, if not all, of
polycystin-2 is normally located within the ER and/or cis-Golgi
(12). Consistent with this finding, polycystin-2 has been local-
ized to the ER within cells and tissues by immunohistochem-
istry, although some signal has also been detected in the baso-
lateral cell membrane of mature mouse and rat kidney tubules
(12, 31, 32). This has led to the suggestion that polycystin-2
might function primarily as an intracellular ER calcium chan-
nel. These results also imply that polycystin-1 and polycystin-2
could be essential members of the same signaling pathway
without directly interacting with each other.
Our results support recent findings showing that transient
co-expression of polycystin-1 and polycystin-2 in CHO cells
reconstitutes a non-selective whole-cell conductance (16). We
extend these findings by demonstrating that polycystin-1 and
polycystin-2 interact to form a stable complex in PKD1 trans-
genic kidney cells, non-transgenic kidney cells, and normal
human adult kidney membranes. In addition, native polycys-
tin-2 was unable to bind truncated forms of human polycystin-1
lacking the C-terminal 205 amino acids in transgenic cells,
thus confirming previous data that the two proteins interact
via their C-terminal tails (10, 11).
Our results also reveal, for the first time, an Endo H-resist-
ant polycystin-1 population interacting with polycystin-2 and
localizing preferentially to the lateral cell membranes of renal
epithelial cells. These results are thus in keeping with recent
immunolocalization findings for native polycystin-1 in Madin-
Darby canine kidney cells (33, 34). Previous studies had re-
vealed intracellular, apical, lateral, and basal cellular locations
for native polycystin-1 in a variety of systems (reviewed in Ref.
15). The demonstration of different polycystin-1 subpopula-
tions may in part explain these apparent discrepancies. Al-
though there is likely to be a dynamic exchange between var-
ious pools of polycystin-1 similar to E-cadherin-catenin
complexes (27), the proteins or signals regulating polycystin-1
trafficking to the plasma membrane are not known. Two stud-
ies have suggested that E-cadherin may itself be such a candi-
date molecule; one described a defect in E-cadherin targeting to
the basolateral domain in cystic ADPKD cells, whereas the
other found that polycystin-1 could co-immunoprecipitate with
E-cadherin from the human pancreatic adenocarcinoma cell
line HPAC (35, 36). It will be interesting to investigate whether
these interactions are also dependent on polycystin-2 binding
in renal tubular cells.
The first descriptions of potential homotypic and heterotypic
interactions between the C termini of polycystin-1 and polycys-
tin-2 came from yeast two-hybrid experiments. These studies
suggested a tendency for homotypic interactions to occur pref-
erentially to heterotypic interactions (10, 11). In one study,
recombinant polycystin-2 was found to homodimerize via a
coiled-coil domain in its C-terminal region, distinct from a more
distal region responsible for heterodimerization with recombi-
nant polycystin-1 (11). We found that native polycystin-2 could
consistently be detected as slower migrating forms even under
denaturing SDS-PAGE. The precise molecular weight of these
FIG. 8. Polycystin-2 exists as several subpopulations in transgenic cells (M7), non-transgenic cells (M8), and NHK. A, apart from
monomeric polycystin-2 (110 kDa, arrowhead), two other high molecular mass bands were consistently detected in M7 and M8 cells by
immunoblotting following SDS-PAGE. These panels represent native polycystin-2 immunoprecipitated by affinity-purified p30 (afp30) from 250 g
of total cell lysate. These bands were more prominent under non-reducing (NR) conditions, suggesting a tendency for polycystin-2 to dimerize or
to bind other proteins. The results shown are a representative experiment of three performed. B, panels representing three adult NHK samples
(NHK1–NHK3) resolved on SDS-PAGE (7.5%) under non-reducing (NR) or reducing (R) conditions. 100 g of NHK was loaded per lane. C,
differential detergent solubility of polycystin-1 and polycystin-2 present in M7 cells. A residual fraction of both proteins remained in the cell pellet
(P) following extraction (S) with 0.5% Triton X-100 but not after extraction with 1% Triton X-100 either singly or in combination with 0.5% Nonidet
P-40. In contrast, E-cadherin (120 kDa) was not fully extracted by 1% Triton X-100 and 0.5% Nonidet P-40. 20 g of each fraction was loaded per
lane.
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forms is uncertain, but they could represent either polycystin-2
oligomers or stable binding to other unidentified proteins. It is
not clear at present whether polycystin-2 (monomers or oli-
gomers) possesses functions independent of polycystin-1. In
CHO cells, heterologous polycystin-2 alone was inactive, but
another group showed that polycystin-2 could gate a non-selec-
tive Ca2 channel independently of polycystin-1 (7, 16). In the
latter study, it is of interest that multiple conductance states
were observed, implying that the different polycystin-2 oli-
gomers could simultaneously be involved in gating (7). It is also
possible that, analogous to the transient receptor potential
family of channel proteins, different combinations of polycys-
tin-2 homo- and heteromultimers could be functionally distinct
(37).
In contrast to the results for polycystin-1, we were unable to
identify an Endo H-resistant fraction of native polycystin-2 in
either cells or tissues. These results raise the question as to
where and how the interaction between polycystin-1 and poly-
cystin-2 takes place. Two models can be proposed. In the first,
polycystin-2 is co-translated and co-assembled with polycys-
tin-1 and the complex then undergoes normal Golgi maturation
(38). Polycystin-2 might undergo a conformational change en-
abling it to bind to polycystin-1 initially within the ER before
being transported to the Golgi. As polycystin-2 remains Endo
H-sensitive, this change is likely to be independent of complex
glycosylation and could, for example, be mediated by changes
in the binding of specific sugars, lipids, cations, or anions. In
the second model, polycystin-2 remains anchored within the
ER membrane and thus remains Endo H-sensitive. ER mem-
brane microdomains enriched in polycystin-2 could then inter-
act with membrane-anchored polycystin-1 within the plasma
membrane or in the membranes of vesicles destined to fuse
with the plasma membrane. The latter model is analogous to
what has been proposed for the interaction of ER-located ino-
sitol trisphosphate receptors with surface-bound transient re-
ceptor potential channels (39). Further kinetic studies will be
necessary to confirm this, but the presence of Endo H-sensitive
and Endo H-resistant forms of polycystin-1 bound to polycys-
tin-2 and the co-sedimentation of polycystin-1 and polycystin-2
in plasma membranes lends support to the first model. Finally,
it should also be noted that Endo H-sensitive secretory proteins
as well as membrane proteins with a mixture of Endo H-
resistant and Endo H-sensitive N-linked glycosylation sites
have been described (40, 41). Thus, Endo H sensitivity alone
would not exclude normal maturation of polycystin-2 through
the Golgi.
Although we have not provided direct evidence of function,
the demonstration of this complex in transgenic and non-trans-
genic cells suggests that the formation of a polycystin complex
is physiological. Its presence in normal adult human kidney,
moreover, implies that a functional complex is still required for
the maintenance of renal tubular structure apart from its role
in tubular maturation during nephrogenesis (42, 43). If this is
the case, then it seems likely that ADPKD cysts may arise not
only in the fetus but also in the adult. The lateral location of
this complex further suggests that the complex may play a
major role in mediating or stabilizing cell-cell adhesion (33).
However, it is probable that it also exerts other functions (5).
Finally, the demonstration of a “Triton-insoluble” fraction of
both proteins suggests that they may be anchored to the actin
cytoskeleton and/or intermediate filaments (27). This finding
also reconciles previous yeast two-hybrid data suggesting that
the C terminus of polycystin-2 can bind to the actin cytoskele-
ton via the adapter proteins, Hax-1 and CD2-AP (13, 14).
In conclusion, we have demonstrated that polycystin-1 and
polycystin-2 can interact in vivo to form a protein complex
localized in part to the lateral plasma membrane domain of
renal tubular cells. We conclude that disruption of this complex
is likely to be of primary relevance to the pathogenesis of cyst
formation in ADPKD and that haploinsufficiency at either lo-
cus could lead to cystogenesis (44, 45).
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